Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Dalbavancin by AbbVie for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: Likelihood of Approval
Dalbavancin is under clinical development by AbbVie and currently in Phase III for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. According to...
Data Insights
Dalbavancin by AbbVie for Mycoses: Likelihood of Approval
Dalbavancin is under clinical development by AbbVie and currently in Phase III for Mycoses. According to GlobalData, Phase III drugs...